Local drug delivery systems and prevention of restenosis.

w x30 Guzman LA, Labhasetwar V, Song C, et al. Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. Circulation 1996;94:1441–1448.w x31 Lee SW, Trapnell BC, Rade JJ, Virmani R, Dichek DA. In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ Res 1993;73:797–807.w x32 Willard JE, Jessen ME, Gerard RD, et al. Recombinant adenovirus is an efficient vector for in vivo gene transfer and can be preferentially directed at vascular endothelium or smooth muscle cells. CirculationŽ .1992;86 I :473. abstract.w x33 Maillard L, Walsh K. Growth-arrest homeobox gene Gax: A molec-ular strategy to prevent arterial restenosis. Schweiz Med Wochen-schr 1996;126:1721–1726.w x34 Chang MW, Barr E, Lu M, Barton K, Leiden JM. Adenovirusmediated overexpression of the cyclinrcyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointimal formation in the rat carotid artery model of balloonangioplasty. J Clin Invest 1995;96:2260–2268.w x35 Chang MW, Ohno T, Gordon D, et al. Adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene inhibits vascular smooth muscle cell proliferation an neointima formation followingballoon angioplasty of the rat carotid artery. Mol Med 1995;1:172– 181.w x36 Guzman RJ, Hirschowitz EA, Brody SL, Crystal RG, Epstein SE, Finkel T. In vivo suppression of injury-induced vascular smoothmuscle cell accumulation using adenovirus-mediated transfer of herpes simplex thymidine kinase gene. Proc Natl Acad Sci USA 1994;91:10732–10736.w x37 Chang MW, Barr E, Seltzer J-Q, et al. Cytostatic gene therapy for vascular proliferative disorders using a constitutively active form of Rb. Science 1994;267:518–522.w x38 Neve RL. Adenovirus vectors enter the brain. Trends Neurosci 1993;16:251–253.w x39 Herz J, Gerard RD. Adenovirus-mediated transfer of low density lipoprotein gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA 1993;90:2812–2816.w x40 Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM.Cellular immunity to viral antigens limits E1-deleted adenovirusesfor gene therapy. Proc Natl Acad Sci USA 1994;91:4407–4411.w x41 Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A inrecombinant adenoviruses improves transgene persistence and de-creases inflammatory responses in mouse liver. Proc Natl Acad SciUSA 1994;91:6196–6200.w x42 Morishita R, Gibbons G, Kaneda Y, Ogihara T, Dzau VJ. Novel invitro gene transfer method for study of local modulators in vascularsmooth muscle cells. Hypertension 1993;21:894–899.w x43 von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapyinhibiting neointimal vascular lesion: in vivo transfer of endothelialcell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995;92:1137–1141.w x44 Plautz G, Nabel EG, Nabel GJ. Introduction of vascular smooth muscle cells expressing recombinant genes in vivo. Circulation 1991;83:578–583.w x45 Simons M, Edelman ER, Rosenberg RD. Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model. J Clin Invest 1994;93:2351–2356.w x46 Morishita R, Gibbons GH, Ellison KE, et al. Single intraluminal delivery of antisense CDC2 kinase and PCNA oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993;90:8474–8478.w x47 Bennett MR, Anglin S, McEwan JR, et al. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invest 1994;93:8294–8298.w x48 Burgess TL, Fisher EF, Ross SL, et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA 1995;92:4051–4055.w x49 van der Giessen WJ, Lincoff M, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996;94:1690–1697.w x50 Murphy JG, Schwartz RS, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Percutaneous polymeric stents in porcine coronary arteries: Initial experience with polyethylene terephthalate stents. Circulation 1992;86:1596–1604.w x51 Baker JE, Nikolaychik V, Zulich A, et al. Fibrin coated stents as adepot to deliver RGD peptide inhibit vascular reaction in atherosclerotic rabbit model. J Am Coll Cardiol 1996;27:197A. abstract.w x52 Lincoff AM, Furst JG, Ellis SE, Topol EJ. Sustained local drug delivery by a novel intravascular eluting stent to prevent restenosis in the porcine coronary artery. J Am Coll Cardiol 1994;23:18A.abstract.w x53 Hardhammer PA, Van Beusekom H, Emanuelsson HV, et al. Reduc-tion of thrombotic events using heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation 1996;93:423–430.w x54 Serruys PW, Emanuelsson H, van der Giessen W, et al. Heparincoated palmaz-schatz stents in human coronary arteries. Early out-come of the Benestent-II pilot study. Circulation 1996;93:412–422.w x55 Williams DO. Dressing up the Palmaz-Schatz stent. Circulation 1996;93:400–402.w x56 Lambert TL, Dev V, Rechavia E, et al. Localized arterial wall drug delivery from a polymer coated removable metallic stent; kinetics,distribution, and bioactivity of forskolin. Circulation 1994;90:1003– 1011.atPenylvaniaStateUniersityonFeruary3,2013http://cardio.oxfordjournals.org/Downladedfrom ( )D. Brieger, E. TopolrCardioÕascular Research 35 1997 405–413413 w x57 Dichek DA, Neville RF, Zwiebel JA, Freeman SM, Leon MB, Anderson WF. Seeding of intravascular stents with genetically engineered endothelial cells. Circulation 1989;80:1347–1353.w x58 Waksman R, Robinson KA, Crocker IR, Gravanis MB, Cipolla GD, King SB. Endovascular low-dose irradiation inhibits neointima formation after coronary artery balloon injury in swine. A possible role for radiation therapy in restenosis prevention. Circulation 1995;91:1533–1539.w x59 Verin V, Popowski Y, Urban P, et al. Intra-arterial beta irradiationprevents a neointimal hyperplasia in a hypercholesterolemic rabbitrestenosis model. Circulation 1995;92:2284–2290.w x60 Waksman R, Robinson KA, Crocker IR, et al. Intracoronary radia-tion before stent implantation inhibits neointima formation in stentedporcine coronary arteries. Circulation 1995;92:1383–1386.w x61 van der Giessen WJ, Serruys PW. B-particle-emitting stents radiate enthusiasm in the search for effective prevention of restenosis. Circulation 1996;94:2358–2360.w x62 Carter AJ, Laird JR, Bailey LR, et al. Effects of endovascular radiation from a B-particle-emitting stent in a porcine coronary restenosis model: A dose response study. Circulation 1996;94:2364– 2368.w x63 Hehrlein C, Stintz M, Kinscherf R, et al. Pure B-particle emitting stents inhibit neointima formation in rabbits. Circulation1996;93:641–645.w x64 Laird JR, Carter AJ, Kufs WM, et al. Inhibition of neointimalproliferation with low-dose irradiation from a B-particle-emittingstent. Circulation 1996;93:529–536. atPenylvaniaStateUniersityonFeruary3,2013http://cardio.oxfordjournals.org/Downladedfrom